BIXT — Bioxytran Income Statement
0.000.00%
Last trade - 00:00
- $24.97m
- $26.17m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 1.63 | 1.27 | 4.21 | 2.14 | 3.83 |
Operating Profit | -1.63 | -1.27 | -4.21 | -2.14 | -3.83 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -1.86 | -2.54 | -4.53 | -2.66 | -4.37 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.86 | -2.54 | -4.53 | -2.66 | -4.37 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -1.86 | -2.48 | -4.03 | -2.46 | -4.28 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.86 | -2.48 | -4.03 | -2.46 | -4.28 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.022 | -0.026 | -0.038 | -0.021 | -0.032 |